Global Clostridium Diagnostics Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Clostridium Diagnostics Market Research Report 2024
Clostridium is a gram-positive bacteria that belongs to the Firmicutes phylum. There are multiple species of Clostridium — Clostridium botulinum, Clostridium difficile, Clostridium perfringens, Clostridium tetani, and Clostridium sordellii, which are responsible for numerous infections. Clostridium tetani is responsible for tetanus, Clostridium botulinum causes botulism, Clostridium perfringes leads to gas gangrene, Clostridium sortellii causes pneumonia, endocarditis, arthritis, peritonitis, and myonecrosis, and Clostridium difficile is responsible for diarrhea.
According to MRAResearch’s new survey, global Clostridium Diagnostics market is projected to reach US$ 4967.5 million in 2033, increasing from US$ 2194.2 million in 2022, with the CAGR of 12.2% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Clostridium Diagnostics market research.
According to the report, one of the major drivers for this market is Rising prevalence of Clostridium-related diseases. Clostridium difficile infection (CDI) is a major cause of hospital-associated GI illness and creates a huge burden on the healthcare system. It is estimated that patients with CDI put a burden of $3.2 billion annually in the US on the healthcare system. Patients with CDI have a longer stay at the hospital, and CDI has been the major cause of large outbreaks of diseases in hospitals. The new molecular diagnostic stool test will replace the current enzyme immunoassay tests.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Clostridium Diagnostics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Abbott
Beckman Coulter
Olympus
Siemens Healthineers
F. Hoffmann-La Roche
BD
bioMerieux
Chrono-log
Corgenix
Diazyme Laboratories
FUJIREBIO DIAGNOSTICS
Hologic
QIAGEN
Sysmex
Thermo Fisher Scientific
Segment by Type
Clostridium Difficile
Clostridium Perfringens
Clostridium Botulinum
Clostridium Tetani
Clostridium Sordellii
Hospitals
Independent Laboratories
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Clostridium Diagnostics report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Clostridium Diagnostics market is projected to reach US$ 4967.5 million in 2033, increasing from US$ 2194.2 million in 2022, with the CAGR of 12.2% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Clostridium Diagnostics market research.
According to the report, one of the major drivers for this market is Rising prevalence of Clostridium-related diseases. Clostridium difficile infection (CDI) is a major cause of hospital-associated GI illness and creates a huge burden on the healthcare system. It is estimated that patients with CDI put a burden of $3.2 billion annually in the US on the healthcare system. Patients with CDI have a longer stay at the hospital, and CDI has been the major cause of large outbreaks of diseases in hospitals. The new molecular diagnostic stool test will replace the current enzyme immunoassay tests.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Clostridium Diagnostics market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Abbott
Beckman Coulter
Olympus
Siemens Healthineers
F. Hoffmann-La Roche
BD
bioMerieux
Chrono-log
Corgenix
Diazyme Laboratories
FUJIREBIO DIAGNOSTICS
Hologic
QIAGEN
Sysmex
Thermo Fisher Scientific
Segment by Type
Clostridium Difficile
Clostridium Perfringens
Clostridium Botulinum
Clostridium Tetani
Clostridium Sordellii
Segment by Application
Hospitals
Independent Laboratories
Clinics
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Clostridium Diagnostics report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source